Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: research hub

OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women

This study, OPTIMA YOUNG, is for younger women with a common type of early breast cancer. It looks at the best way to treat this cancer to stop it from coming back, by comparing different medications and how well they work.